

LIST OF CONTENT

Chapter	Page
I INTRODUCTION.....	1
Statement of the problem.....	1
Objectives.....	3
II REVIEWS OF RELATED LITERATURE AND RESEARCH.....	4
Diabetes care.....	4
Basic knowledge about diabetes.....	4
Importance of glycemic control.....	4
Assessment of glycemic control.....	5
Therapeutic options in diabetes.....	7
Guideline for diabetes management.....	7
Thiazolidinediones.....	10
Mechanism of action.....	10
Therapeutic effect of thiazolidinediones.....	11
Cost-effectiveness study of thiazolidinediones.....	13
Economic evaluation in healthcare system.....	14
Importance of perspective in economic evaluation.....	14
Types of economic evaluation.....	15
Cost estimation.....	15
Effectiveness	17
Disease modeling.....	19
Types of model.....	19

LIST OF CONTENT (CONT.)

Chapter	Page
Sensitivity analysis.....	21
Diabetes models.....	22
The CORE diabetes model.....	22
III RESEARCH METHODOLOGY.....	25
Overview of the study design.....	25
Markov model.....	25
Myocardial infarction sub-model.....	25
Angina sub-model.....	26
Congestive heart failure sub-model.....	26
Stroke sub-model.....	26
Peripheral vascular disease sub-model.....	27
Neuropathy sub-model.....	27
Foot ulcer sub-model.....	27
Retinopathy sub-model.....	27
Macular edema sub-model.....	28
Cataract sub-model.....	28
Nephropathy sub-model.....	28
Hypoglycemia sub-model.....	29
Ketoacidosis sub-model.....	29
Lactic acidosis sub-model.....	29

LIST OF CONTENT (CONT.)

Chapter	Page
Non-specific mortality sub-model.....	29
Population inputting in the model.....	31
Interventions and controls.....	34
Transition probabilities used in the CORE model.....	36
Clinical effectiveness data.....	38
Cost data.....	39
Overview of costs used in the model.....	39
Buddhachinaraj hospital database.....	39
Published literatures.....	47
The government reports.....	51
Cost estimated form micro-costing technique.....	52
DRGs.....	53
Data analysis.....	55
First order simulation.....	55
Second order simulation.....	56
Model assumptions.....	57
IV RESULTS.....	57
First order simulation.....	58
Base-case analysis.....	58
Sensitivity analysis.....	65

LIST OF CONTENT (CONT.)

Chapter	Page
Second order simulation.....	65
V CONCLUSION.....	67
BIBLIOGRAPHY.....	72
APPENDIX.....	82
A: Number of Ages-Sex Specific Death Rate per 1,000 Populations.....	83
B: Transition probabilities of death from dialysis.....	85
C: Diabetes complications costs calculated from Buddhachinaraj hospital database.....	87
D: Incremental cost-effectiveness ratio using median diabetes complication cost calculated from Buddhachinaraj hospital.....	89
E: Cumulative cost of 40 years time horizon.....	91
F: Cumulative incidence of cardiovascular disease of the pioglitazone group and the rosiglitazone group.....	93
G: Breakdown of costs at the end of simulation.....	95
H: Cumulative incidences of diabetes complications at the end of 40 years simulation.....	97
BIOGRAPHY.....	100

LIST OF TABLES

Table	Page
1 Correlation between A1c level and mean plasma glucose levels on multiple testing over 2-3 months based on data from DCCT.....	6
2 Oral hypoglycemic agents.....	9
3 Recommendations for diabetes patients.....	10
4 Mean% change of A1c from baseline of thiazolidinediones in the Meta-analysis	12
5 Mean% change of A1c from baseline of the thiazolidinediones combination therapy in the Meta-analysis.....	12
6 Lipid effect of thiazolidinediones in the Meta-analysis.....	13
7 Base line characteristics of the population.....	32
8 Baseline characteristics of Thai cohort used in the model in part of management	34
9 Side effect and failure rate of thiazolidinediones.....	35
10 The surrogate outcomes which can predict the progression rate of the final outcome.....	37
11 Risk reduction influenced by 1% decrease in A1c.....	38
12 Clinical effectiveness of the treatment used in the analysis.....	39
13 Diabetes ICD-10 diagnoses in Buddhachinaraj hospital database.....	41
14 Consumer price index of Thailand in medical care expenditure	42
15 Buddhachinaraj cost to charge ratio.....	42
16 Diagnosis code used to identify diabetes patients to each complication group	43
17 Number of subject and observation in each complication including in the analysis.....	44

LIST OF TABLES (CONT.)

Table	Page
18 Costs of the diabetes complications calculated from Buddhachinaraj hospital database.....	45
19 Costs of hemodialysis.....	48
20 Costs of peritoneal dialysis.....	49
21 Cost of renal replacement therapy.....	50
22 Treatment costs	51
23 Thai diabetes related costs used in the CORE Diabetes model.....	53
24 Summary of clinical outcomes in base case analysis.....	58
25 Time alive and free of complication in base case analysis.....	59
26 Cumulative incidence at the end of 40 years simulation.....	60
27 Summary of cost and incremental cost effectiveness analysis in base case results.....	62
28 Sensitivity analyses on the incremental costs effectiveness ratio.....	63
29 Number of ages-sex specific death rate per 1,000 populations, 2004.....	84
30 Transition probabilities of death from dialysis.....	86
31 Diabetes complications costs calculated from Buddhachinaraj hospital database	88
32 Incremental cost-effectiveness ratio using median diabetes complication cost calculated from Buddhachinaraj hospital.....	90

LIST OF FIGURES

Figure	Page
1 Action of the thiazolidinediones on activation of the PPAR γ receptor.....	11
2 The possible pathways of relationship between surrogate outcome and final outcome.....	18
3 Decision tree model.....	20
4 Markov model.....	21
5 The CORE diabetes model structure.....	30
6 Treatment pathway of thiazolidinediones induced edema.....	35
7 The relationship of interventions on surrogate outcome and the final outcome estimated in the model.....	36
8 Survival rate.....	59
9 Cumulative incidence of stroke.....	61
10 Sensitivity analyses in tornado diagram.....	64
11 The incremental cost per quality adjusted life expectancy scatter plot.....	65
12 Acceptability curve.....	66
13 Cumulative cost of 40 years time horizon.....	92
14 Cumulative incidence of congestive heart failure.....	94
15 Cumulative incidence of myocardial infarction.....	94
16 Cumulative incidence of angina.....	94
17 Breakdown of costs at the end of simulation.....	96
18 Cumulative incidence of eye disease.....	98
19 Cumulative incidence of cardiovascular disease.....	98
20 Cumulative incidence of renal disease.....	99
21 Cumulative incidence of ulcer and amputation.....	99